professional and social network for cardiology

Cardiology professional network for building relationships in clinical practice, education, career, research, & industry

Find us on Facebook

Blog Posts


Reascher:In my opinion, at this time Losartan 150 mg is much better than 50 mg in terms of the edendpoints. There is a 10% decrease with 150 mg of Losartan in terms of reducing death or heart failure hospitalization. The HEAALstudy is the first to verify that 150 mg of Losartan has a therapeutic effect in the treatment of heart failure. Also, in Chinathe first time RAS blockade used to treat heart failure were ACE inhibitors but we have about 20% of patients with coughafter…


Posted by min zhao on March 9, 2011 at 8:00pm


Reascher:I’d like to talk today about heart failure specifically. We have seen several lead breaking heart failure trials presented here at AHA 2009 and one of those trials was the HEAAL study. Can you give us your brief opinion on the HEAAL study as well as any comments about how we can evaluate it? Additionally, what do you think the contribution is to the progress regarding how we can treat heart failure?

 Prof. Nissen:We don’t use Losartan very…


Posted by min zhao on March 9, 2011 at 8:00pm — 1 Comment

What about in those patients with AF?

Reascher:What about in those patients with AF?


Prof. Jessup : Physicians often times use the wrong drugs to slow heart rate or they may combine a calcium antagonist drug in someone who has a poor ejection fraction and that is the wrong thing to do. I think that the guidelines that came out today are very helpful.

Posted by min zhao on March 9, 2011 at 7:59pm — 1 Comment

What is the most efficient or best way to screen out patients who are at high risk for heart failure?

Reascher:What is the most efficient or best way to screen out patients who are at high risk for heart failure?


Prof. Jessup : In general physicians do understand who is at high risk. High-risk patients include patients in the hospital frequently, those with an elevated BUN and creatinine, patients with low blood pressure, or multiple comorbidities, which this session was about. Most physicians will understand those patients to be high risk but do not necessarily act on that…


Posted by min zhao on March 9, 2011 at 7:57pm


Welcome to CardiologyCommons!

Welcome to CardiologyCommons - a professional and social network for cardiology! How can you use CardiologyCommons?

• Connect with colleagues and build professional network in cardiology
• Find and share interesting cases (unlimited storage space)
• Find cardiology answers and advice
• Form an online group for your society, practice, and department
• Seek best and unpublished cardiology jobs and cardiologist career opportunities
• Stay up to date via News, Cardiology Tools, and Cardiology Resources



  • Add Videos
  • View All

Latest Activity



What is ideal cholesterol level.....Is the notion as low as good is valid

As the new data and results of trials come guidelines are made.Currently acca/aha has given a good deal of cut off values for various catogeries of patients.But the most basic and commenly asked q…Continue

Started by fayaz mujtaba Oct 31, 2010.





Cardiology News (from

Acurate Neo Valve Holds Its Own Against Sapien 3

Both transcatheter valves had very high success rates, with one study author suggesting the Acurate Neo, investigational in the US, "is more or less an all-comer valve like the Sapien."
Medscape Medical News

A Corrosive Force in Medical Care

Are RVUs slowly but surely killing the art of medicine?

Oct 20 Cardiology News

Secondary AF, Heart failure statistics, DOAC bleeding rates, uncontrolled hypertension and stroke risk factors are discussed by John Mandrola in this week's podcast. on Medscape

TAVR Looms Large in First AUC Document for Severe Aortic Stenosis

There are more treatment options than ever before, but guidelines only go so far when the patient is 90-something, frail, and with multiple chronic disorders, for example.
Medscape Medical News

Hope and Hazards for Patients After Fontan Procedure

Drs Egbe and Said join Dr Melissa Lyle to discuss the progress and challenges in managing patients who have undergone Fontan palliation.
Mayo Clinic

© 2017   Created by CardiologyCommons Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service